V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320003204 | 320001922 | 1.63 | 60.4 | Adjuvant (A) | null | 2017-11-08 | Oxaliplatin + Modified de Gramont | N | N | 320019030 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320003205 | 320001923 | 1.79 | 63.6 | Disease modification (D) | 2017-03-07 | 2017-03-07 | Carboplatin + Etoposide iv&po | 02 | N | 320019043 | CARBO + FLUOROURACIL |
| 320003206 | 320004969 | 1.61 | 46 | Palliative (P) | 2016-08-11 | 2016-08-19 | CETUXIMAB + RT | N | N | 320019049 | IPILIMUMAB |
| 320003207 | 320001924 | 1.79 | 102 | Curative (C) | 2013-10-04 | 2013-10-11 | Carboplatin+Fluorouracil 4 or 5 day | N | Y | 320019064 | CISPLATIN + GEMCITABINE |
| 320003208 | 320001925 | 1.56 | 42.2 | Palliative (P) | 2014-01-06 | 2014-01-10 | ECarboF | Y | N | 320019066 | CETUXIMAB + RT |
| 320003209 | 320001926 | 1.66 | 77.4 | Adjuvant (A) | null | 2014-10-22 | Carboplatin + Vinorelbine Oral | null | null | 320019077 | ENZALUTAMIDE |
| 320003210 | 320001927 | 1.66 | 66 | Palliative (P) | 2016-02-18 | 2016-02-26 | PEMBROLIZUMAB | N | N | 320019099 | CARBOPLATIN + RT |
| 320003211 | 320001927 | 1.67 | 79 | Adjuvant (A) | 2016-10-13 | 2016-11-02 | CISPLATIN + GEMCITABINE | N | N | 320019099 | CARBOPLATIN + RT |
| 320003212 | 320001928 | null | null | Palliative (P) | null | 2015-03-17 | BCG Intravesical | N | N | 320019104 | CARBOPLATIN + PEMETREXED |
| 320003213 | 320001929 | 1.87 | 67.3 | Curative (C) | 2017-04-05 | 2017-04-07 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | 02 | Y | 320019113 | CARBOPLATIN + VINORELBINE |
| 320003214 | 320001930 | 1.6 | null | Palliative (P) | 2016-12-03 | 2016-12-11 | Capecitabine + Cisplatin | N | N | 320019114 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003215 | 320001931 | null | null | Neo-adjuvant (N) | null | 2013-03-16 | Capecitabine + Mitomycin | null | null | 320019117 | CAP + RT |
| 320003216 | 320001932 | 1.68 | 64.8 | Curative (C) | 2016-10-15 | 2016-10-19 | Temozolomide + RT | Y | null | 320019138 | NOT MATCHED |
| 320003217 | 320001933 | 1.7 | 127 | Palliative (P) | 2017-11-01 | 2017-11-01 | CAPECITABINE + OXALIPLATIN | 2 | N | 320019150 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003218 | 320001934 | 1.61 | 47.2 | Adjuvant (A) | 2016-10-16 | 2016-10-25 | Bortezomib + Cyclophos + Dex | N | N | 320019164 | IPILIMUMAB + NIVOLUMAB |
| 320003219 | 320001935 | null | null | Palliative (P) | 2014-02-10 | 2014-02-11 | CETUXIMAB | N | N | 320019167 | CETUXIMAB |
| 320003220 | 320001936 | 1.61 | null | Palliative (P) | 2012-01-25 | 2013-04-18 | Cisplatin + Gemcitabine (D 1 & 8) | null | null | 320019168 | CARBOPLATIN + ETOPOSIDE |
| 320003221 | 320001937 | 1.72 | null | Curative (C) | 2013-05-17 | 2013-05-29 | VISMODEGIB | N | Y | 320019172 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320003222 | 320001938 | 1.61 | 89 | Palliative (P) | 2017-04-23 | 2017-04-23 | DABRAFENIB | N | N | 320019181 | PACLITAXEL |
| 320003223 | 320001938 | 1.73 | 84.5 | Curative (C) | 2017-12-27 | 2017-12-29 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 320019181 | CISPLATIN + PEMETREXED |
| 320003224 | 320001939 | 1.74 | 59.2 | Neo-adjuvant (N) | null | 2015-12-12 | POUT TRIAL | N | N | 320019190 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003225 | 320001940 | 1.59 | 136 | Curative (C) | 2017-09-25 | 2017-10-07 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 320019194 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003226 | 320001941 | 1.77 | 65 | Disease modification (D) | 2015-10-25 | 2015-10-26 | BCG Intravesical | 02 | N | 320019200 | BCG |
| 320003227 | 320001942 | 0 | 84.4 | Palliative (P) | 2015-08-06 | 2015-09-02 | Bevacizumab + Paclitaxel | N | N | 320019210 | THALIDOMIDE |
| 320003228 | 320001943 | 1.58 | 71.2 | Palliative (P) | null | 2016-01-08 | Capecitabine + Oxaliplatin 14day | null | null | 320019211 | CAPECITABINE + OXALIPLATIN |
| 320003229 | 320001944 | 1.75 | 77 | Adjuvant (A) | 2015-05-16 | 2015-06-07 | CETUXIMAB + RT | N | N | 320019222 | CISPLATIN + ETOPOSIDE |
| 320003230 | 320001945 | 1.89 | 88 | Curative (C) | 2015-01-31 | 2015-02-21 | CARBOPLATIN + RT | 2 | N | 320019230 | CARBOPLATIN + RT |
| 320003231 | 320001946 | 1.79 | 97.4 | null | 2012-01-19 | 2013-04-16 | Carboplatin + Etoposide iv&po | 02 | N | 320019255 | CARBOPLATIN + RT |
| 320003232 | 320001947 | 1.61 | 40.2 | Palliative (P) | 2017-01-25 | 2017-01-26 | Trial Unspecified | N | N | 320019266 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003233 | 320001947 | 1.7 | 54.1 | Curative (C) | 2016-04-19 | 2016-04-25 | Trial Unspecified | N | N | 320019266 | ENZALUTAMIDE |
| 320003234 | 320001948 | 1.7 | 59 | Neo-adjuvant (N) | 2015-08-30 | 2015-09-12 | CARBOPLATIN + RT | 02 | N | 320019274 | ICON TRIAL |
| 320003235 | 320001948 | 0 | 68.5 | Curative (C) | 2016-04-24 | 2016-05-05 | CNS LGG 2004 03 vinc weekly+ carbo | Y | N | 320019274 | CARBOPLATIN + RT |
| 320003236 | 320001949 | 1.63 | 96 | Neo-adjuvant (N) | 2017-10-15 | 2017-10-22 | Bevacizumab 15mg/kg | N | N | 320019285 | CISPLATIN + GEMCITABINE |
| 320003237 | 320001949 | 1.73 | 77.4 | Curative (C) | 2013-05-14 | 2013-05-14 | EOX | null | null | 320019285 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003238 | 320001950 | 1.73 | 69.3 | Palliative (P) | 2018-03-06 | 2018-03-10 | Cisplatin+Gemcitabine (Days 1&8&15) | N | N | 320019292 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003239 | 320001951 | 1.87 | 0 | Adjuvant (A) | 2014-12-17 | 2014-12-17 | FLUOROURACIL + MITOMYCIN + RT | N | N | 320019296 | CISPLATIN + GEMCITABINE |
| 320003240 | 320001952 | 1.58 | 54.8 | Adjuvant (A) | null | 2014-01-04 | BEVACIZUMAB + CARBO + PACLITAXEL | N | 2 | 320019297 | IMATINIB |
| 320003241 | 320001953 | null | 71.9 | Curative (C) | 2019-01-05 | 2019-01-05 | Cisplatin + Fluorouracil + RT 5day | 02 | Y | 320019298 | ECX |
| 320003242 | 320001954 | null | 66.9 | Disease modification (D) | null | 2014-05-23 | Bevacizumab 7.5mg/kg | null | null | 320019304 | DOXORUBICIN + IFOSFAMIDE |
| 320003245 | 320001957 | 1.65 | 72.4 | Curative (C) | 2017-04-25 | 2017-05-16 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320019334 | CARBOPLATIN + RT |
| 320003246 | 320001958 | 1.66 | null | Palliative (P) | 2013-08-04 | 2013-08-08 | Carboplatin + Cetux + FU (Cycle 1) | 2 | N | 320019348 | CARBOPLATIN + PEMETREXED |
| 320003247 | 320001959 | 1.78 | 76.5 | Palliative (P) | 2016-07-12 | 2016-07-22 | null | N | N | 320019352 | TIP |
| 320003248 | 320001960 | 1.61 | 76.8 | Adjuvant (A) | 2015-05-02 | 2015-05-10 | CETUXIMAB + RT | 01 | N | 320019354 | CETUXIMAB + RT |
| 320003249 | 320001960 | 1.6 | 60.3 | Palliative (P) | 2014-07-22 | 2014-07-29 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320019354 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003250 | 320001960 | 1.59 | 60 | Palliative (P) | 2014-01-03 | 2014-01-08 | Carboplatin + Etoposide IV 3 day | N | N | 320019354 | CAPECITABINE |
| 320003251 | 320001961 | 1.52 | 46 | Palliative (P) | 2014-09-30 | 2014-10-14 | Carboplatin + Etoposide iv&po | N | N | 320019382 | CISPLATIN + ETOPOSIDE |
| 320003252 | 320001962 | 1.65 | 61.7 | null | 2016-11-30 | 2016-11-30 | CETUXIMAB + RT | 01 | N | 320019389 | DE-ESCALATE TRIAL |
| 320003253 | 320001963 | 1.65 | 69.3 | Palliative (P) | 2016-03-25 | 2016-04-08 | Paclitaxel (2 or 3 weekly) | 02 | N | 320019415 | ICON TRIAL |
| 320003254 | 320004976 | 1.85 | 69.4 | null | 2013-08-21 | 2013-09-26 | CETUXIMAB | N | N | 320019440 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003255 | 320001964 | 1.56 | 47 | Adjuvant (A) | 2015-06-06 | 2015-06-10 | IMATINIB | N | null | 320019444 | TRIAL |